McKesson Corporation
807.63+3.04 (+0.38%)
Oct 29, 4:00:02 PM EDT · NYSE · MCK · USD
Key Stats
Market Cap
100.46BP/E (TTM)
32.36Basic EPS (TTM)
24.96Dividend Yield
0%Recent Filings
8-K
McKesson segment realignment announced
McKesson Corporation announced a realignment into four reportable segments—North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective for reporting starting Q2 fiscal 2026, reflecting CEO resource allocation. This shift, driven by evolving healthcare needs, includes supplemental historical data showing FY2025 revenues of $359,051 million across segments, with no impact on prior consolidated statements. Norwegian operations head to 'Other' amid an August 2025 sale agreement. New structure sharpens focus.
10-Q
Q1 FY2026 results
McKesson posted solid Q1 FY2026 results, with revenues jumping 23% year-over-year to $97.8B, fueled by 25% growth in the U.S. Pharmaceutical segment from higher specialty drug volumes and retail national accounts, while gross profit rose 4% to $3.3B but margins slipped to 3.4% from 4.0% due to mix shifts. Operating income held steady at $1.0B, yet net income attributable to McKesson dipped 14% to $784M and diluted EPS fell 11% to $6.25, reflecting a $189M bad debt hit from Rite Aid's bankruptcy and higher taxes at 20.9% versus 11.4%; EPS reconciles cleanly to 125.5M diluted shares with no anti-dilution flags. Key drivers included 16% RxTS revenue growth from tech services and a 2% uptick in Medical-Surgical, offset by restructuring charges of $47M. Acquisitions bolstered the balance sheet, closing PRISM Vision in April for $874M cash (80% stake, $432M goodwill, $510M intangibles) and Core Ventures in June for $2.5B cash (70% stake, $806M goodwill, $2.3B intangibles over finite lives), funded partly by $2.0B in new notes; cash ended at $2.4B with $7.8B total debt and full revolver availability under covenants. Free cash flow wasn't disclosed in the 10-Q. Ongoing opioid litigation poses a persistent risk, with $6.4B in reserves for settlements.
8-K
McKesson Q1 revenue surges
McKesson reported Q1 fiscal 2026 revenues of $97.8 billion, up 23% year-over-year, fueled by U.S. pharmaceutical growth and oncology acquisitions, yet GAAP EPS fell to $6.25 from $7.00 due to a $189 million Rite Aid bad debt hit. Adjusted EPS climbed 5% to $8.26, prompting a raised full-year guidance of $37.10-$37.90. Acquisitions bolstered specialty capabilities. Strong results shine through.
8-K
Shareholder meeting results
McKesson Corporation's shareholders overwhelmingly elected all 11 board nominees on July 30, 2025, with Dominic J. Caruso topping votes at 99.5 million for and just 881,000 against. Ratification of Deloitte & Touche LLP as auditors for fiscal 2026 passed with 102.2 million in favor, while advisory approval of executive compensation garnered 91.8 million yes votes amid 8 million no's. Strong support signals board stability. Yet dissent on pay highlights scrutiny.
8-K
McKesson boosts FY26 EPS outlook
McKesson Corporation raised its Fiscal Year 2026 Adjusted Earnings per Diluted Share guidance from $36.75-$37.55 to $36.90-$37.70, signaling stronger operational momentum amid investor meetings on June 9, 2025. The company reaffirmed its full-year effective tax rate of 17%-19%, with first-half rates edging higher at 17%-20%. All other prior guidance stands. Forward-looking projections carry risks from legal disputes and market shifts.
IPO
Website
Employees
Sector
Industry
CAH
Cardinal Health, Inc.
164.47+1.68
COR
Cencora, Inc.
333.17-2.47
CVS
CVS Health Corporation
80.60-1.60
HLYK
HealthLynked Corp.
1.63+0.00
HSIC
Henry Schein, Inc.
62.32-0.89
OMI
Owens & Minor, Inc.
5.22-0.06
SRXH
SRX Health Solutions, Inc.
0.34-0.03
THC
Tenet Healthcare Corporation
209.14+4.52
UNH
UnitedHealth Group Incorporated
355.26-12.58
WST
West Pharmaceutical Services, I
284.86+1.37